WHA President-Elect Announcement

Dear colleagues,  

I am delighted to announce that after a comprehensive and competitive selection process, Dee Lee has been selected by the World Hepatitis Alliance (WHA) global board to serve as president-elect beginning January 2025.  

Dee Lee has served as the Director of Inno Asia since 2023, following his tenure as Director of the Inno Community Development Organisation from 2007-2022. He was appointed as WHA WPRO Regional Board Member from 2015-2019 and resumed the role again in 2024. In addition, he is the Chair of the Steering Group for the International Liver Cancer Movement, a Fellow of the Asia Society, and a member of both the Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP) and the International Coalition to Eliminate Hepatitis B (ICE-HBV).

As a person living with hepatitis, Dee’s fight in China has been against the injustices faced by hepatitis patients unable to get access to treatment and employees wrongfully terminated based on their blood test results. From 2010-2014, Dee worked to eliminate the hepatitis B screening policy in 200 factories covering more than one million workers directly.

In 2016, Dee joined the then WHA President, Charles Gore in Geneva to finalise the introduction of viral hepatitis in the Global Health Sector Strategy with the goal of ending hepatitis before 2030. He has spoken in countless seminars to raise awareness of hepatitis, and the stigma and discrimination attached to it. More than twenty of his journals have been published with the support of the community.

During his break from the WHA Board, Dee realised that focusing solely on China, fighting stigma and discrimination, or raising awareness was not enough. Aware that his hepatitis B status could lead to liver cancer, he renewed his committment to work with the community and WHA. He determined to speed-up the process of a functional cure for hepatitis B and reduce stigma and discrimination as barriers to the elimination of viral hepatitis.

Dee understands the mission and vision of WHA and over the next year as president-elect, he and I will work closely together to prepare him for the presidency and to assure a smooth transition. Together with our board and the staff team, we will strengthen WHA’s position on the global stage, use our voice to empower the millions living with viral hepatitis and help make WHA’s mission a reality.  

Please join me in congratulating Dee Lee on his appointment and welcoming him aboard! 

Rachel Halford, WHA President

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close